PARIS (Reuters) – French drugs and healthcare group Sanofi (SASY.PA) said on Tuesday it had signed a rights deal with Roche (ROG.S) for the ‘Tamiflu’ product in the United States.
The deal will give Sanofi exclusive U.S. over-the-counter (OTC) rights to Tamiflu, which is used for the prevention and treatment of flu.
“This is a strategic and important transaction for us as we strive to continually bring innovations to the market,” said Alan Main, executive vice president of Sanofi’s consumer healthcare division, in a statement.
